Highlights from AACR 2026

We exhibited and presented two scientific posters that highlight the evolving role of circulating tumor cells (CTCs) in cancer progression and management:

Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients.

Depletion of circulating tumor cells using an automated device with non-hemolytic affinity-based substrates

These studies reflect our continued efforts to better understand CTC biology—not only as indicators, but as active contributors to metastasis.

At the center of this work is OncoMetastat®, our patented investigational extracorporeal blood-processing platform. It is envisaged to selectively capture and study circulating tumor cells from a patient’s bloodstream while maintaining blood integrity. Designed with a strong focus on precision and safety, the current prototype is under evaluation for its potential relevance in metastasis research and broader cancer management.

Some Interesting Clicks

Video Highlights

We look forward to engaging with researchers, clinicians, and innovators shaping the future of oncology.